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ABSTRACT 
Objective: To investigate in vitro and in vivo antidiabetic activity of Barleria noctiflora (B. noctiflora) fractions on high-fat diet (HFD) with low dose 
Streptozotocin (STZ) induced type-2 diabetes in rats. 
Methods: B. noctiflora were successively extracted and then fractionated by Ethyl acetate and n. butanol. The in vitro antidiabetic activity from α-
amylase and α-glucosidase was used to evaluate the potential activity of the fractions. The in vivo antidiabetic activity is evaluated against HFD/STZ 
induced type-2 diabetic in rats at a dose of 100 mg/kg, 200 mg/kg and 400 mg/kg, p. o for 28days. 
Results: Ethyl acetate fraction of B. noctiflora (EAFBN) showed the highest antidiabetic activity and IC50
Conclusion: The EAFBN is a potent hypoglycemic agent and beneficial in reducing the elevated blood glucose level, improve the lipid profile and 
insulin level and histopathological changes in the pancreas of HFD/STZ-induced non-genetic rat model of type-2 diabetes mellitus. 
 values of α-amylase inhibition 
(114.7±0.15) and α-glucosidase inhibition (104.93±0.28) than other fraction. In HFD/STZ (40 mg/kg) diabetic rats the EAFBN showed a dose 
dependent significant hypoglycemic property from body weight, blood glucose, serum lipids, serum cholesterol, serum triglycerides, urea, 
creatinine, hepatic enzymes and liver glycogen levels. The EAFBN significantly (P<0.01) increase the level of serum insulin. Histologically, focal 
necrosis was observed in the diabetic rat pancreas; however, was less obvious in treated groups. 
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INTRODUCTION  
Diabetes mellitus is a chronic disease caused by inherited and 
acquired deficiency in the production of insulin by the pancreas or 
by the ineffectiveness of the insulin produced. Such as deficiency 
results in increased concentrations of glucose in the blood, which is 
turn damage to various macro and microvascular complication 
leading to damage, dysfunction and failure of various organs, 
especially the eyes, kidneys, nerves, heart and blood vessels [1]. 
Estimated 366 million people worldwide (8.3 % of adults) had 
diabetes in 2011 and was predicted to go up to 552 million people 
(one adult in 10) by the year 2030 [2]. 
Glucose homeostasis, especially the postprandial increase in blood 
glucose levels, is facilitated by enteric enzymes, namely α-amylase 
and α-glucosidase attached to the brush border of the intestinal cells 
[3]. Alpha-amylase (α-1, 4 glucan-4-glucanohydrolase) at first 
converts starch to oligosaccharides by hydrolyzing α-1,4-glucan 
bonds. Thus, the first reaction in the digestion of carbohydrates is 
initiated by α-amylase by forming oligosaccharides. Unabsorbed 
carbohydrates (disaccharides and oligosaccharides) will then get 
bound to α-glucosidase enzymes in the brush border of small 
intestine [4]. Inhibition of this carbohydrate digesting enzymes 
prolongs the overall carbohydrate digestion time by delaying its 
breakdown, causing a decrease in the rate of glucose absorption and 
consequently blunting the postprandial rise in plasma glucose [5]. 
Streptozotocin is used to induce both type 1 and type 2 diabetes 
mellitus in rats. A high fat diet with STZ injected intraperitoneally at 
a dose of (40 mg/kg b.w.) rats produced type 2 diabetes mellitus 
showing sustained hyperglycemia [6].
Herbal medicine is prepared from various plant part to contain 
many bioactive compounds used primarily for treating. Due to the 
demand in the field of herbal medicines, it has become necessary of 
systematic knowledge about herbal drugs. The safety of herbals, it is 
better not to bury our phytotherapeutic heads in the sand like a 
frightened ostrich in the hope that herbal health problems will 
dissolve by themselves. Thus, we should accept that herbal 
medicines entail certain health risks and to actively look out for 
safety problems associated with herbal medicines several 
considerations [7]. Consistency in composition and biological 
activity are essential requirements for the safe and effective use of 
therapeutic agents. Quality is the critical determinant of safety and 
efficacy of botanical medicines [8].  
  
Barleria noctiflora L. (B. noctiflora), belongs to the family 
Acanthaceae, which is being widely used as Folk and Ayurvedic 
medicine. It is widely distributed throughout the tropical region of 
India, Africa, Sri Lanka and other parts of Asia [9]. The plant has 
more important medicinal uses, many of the members of the 
Acanthaceae family are used as a medication for asthma [10]. Most 
of the Barleria species are potent anti-inflammatory, analgesic, 
antileukemic, antitumor, anti-hyperglycemic, anti-amoebic, virucidal 
& antibiotic. The plant was reported to possess antioxidant. Herbal 
medicines have a major role in the treatment of diabetes since these 
drugs are comparatively safer and free from major side effects. The 
B. noctiflora is used in the folklore medicine of diabetes mellitus in 
India [11]. However, the literature indicates that there is no 
scientific evidence to support the hypoglycemic effect of B. 
noctiflora. Hence, in this study the fraction of B. noctiflora was used 
to perform inhibitory studies on enzymes α-amylase, α-glucosidase 
and Hypoglycemic effects of ethyl acetate fraction of B. noctiflora 
(EAFBN) on high fat fed with low dose Streptozotocin-induced 
diabetes in rats. This evaluation is required to establish potential 
hypoglycemic effects in type 2 diabetes of this valuable herbal 
preparation. 
MATERIALS AND METHODS 
Drugs and chemicals 
Glucose assay, cholesterol, low-density lipoprotein cholesterol 
(LDL), high-density lipoprotein cholesterol (HDL), triglyceride assay 
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kits (Agappe Diagnostics, Kerala, India). Streptozotocin, α-amylase 
(HiMedia, Mumbai, India) and potato starch, maltose (Merck Ltd, 
Mumbai, India), and α-glucosidase (Sisco lab Ltd, Mumbai, India), 
Tween-80 (SD fine chemicals, Mumbai, India) were purchased for 
the study. Glibenclamide (Aventis Pharma, Mumbai, India) and 
Acarbose (Orchid Pharma Ltd, Chennai, India) were obtained as a 
gift sample. All the other chemicals used in the study were of 
analytical grade and were obtained commercially. 
Instrument used 
Shimadzu 1700 UV/Vis Spectrophotometer, Maxlyzer ultra semi 
auto analyzer, systronics MKVI digital pH meter and SD check 
glucometer. 
Collection of plants 
B. noctiflora was collected during the winter season in and around 
Erode District, Tamilnadu, India. It was identified and authenticated 
by Prof. P. Jayaraman, Director, National Institute of Herbal Science, 
Chennai-45, Tamilnadu, India (Ref no: PARC/2011/1015), and the 
voucher specimen was deposited at the same institute for future 
reference. 
Preparation of fraction 
Five hundred grams of shade-dried, powdered aerial part of B. 
noctiflora was extracted using soxhlet apparatus, successively with 
petroleum ether, chloroform, and ethanol for 72 h each. The 
ethanolic extract, dried and prepared separately, the solvents were 
evaporated in vacuum to obtain residues of the extract. The 
fractionation of ethanol extract was done using solubility profile 
[12]. 20 g of dried ethanol extract was taken in a stoppered flask, 
containing 200 ml of water and shaken mechanically for 1-2 h in a 
flask shaker. The ethanol extract was not completely soluble in 
water. The water insoluble portion of ethanol extract was separated 
using filtration and further fractioned with ethyl acetate and n-
butanol using the same procedure. The supernatants obtained from 
the above fraction were concentrated and evaporated to dryness 
and their percent yield was determined. The ethyl acetate fraction of 
B. noctiflora (EAFBN) and n-butanol fractions of B. noctiflora 
(NBFBN) were used to the in-vitro antidiabetic activity. Since in vitro 
antidiabetic activity was found in the ethyl acetate fraction, and it 
was suspended in 1% Tween 80 freshly was prepared just before 
administration to the rats.  
In vitro antidiabetic studies 
In vitro antidiabetic studies were carried out by α-amylase and α-
glucosidase enzyme inhibitory activity in ethyl acetate and n-butanol 
fractions of B. noctiflora. 
In vitro inhibition of α-amylase 
The different concentrations (5–1000 μg/ml) of ethyl acetate and n-
butanol fractions of B. noctiflora/standard Acarbose were prepared 
in dimethyl sulfoxide from 1 mg/ml stock solution and 500 μl of 
test/standard was added to 500 μl of α-amylase (0.5 mg/ml) and 
was incubated for 10 min at room temperature. Then added 500 μl 
of 1% starch solution and incubated for another 10 min. After that 1 
ml of the 3, 5-dinitrosalicylicacid as a coloring reagent was added to 
the reaction mixture and heated in a boiling water bath for 5 min. 
After cooling, it was diluted with 10 ml of distilled water. The 
absorbance was then measured at 540 nm against the reagent blank. 
The α-amylase inhibition was expressed as a percentage of 
inhibition and the IC50
% inhibition = [(Abs of control–Abs of test)/Abs of control] X 100 
 values determined by linear regression plots 
with varying concentration of fraction against percentage inhibition 
[13]. The percentage inhibition was calculated employing the 
following formula. 
In vitro inhibition of α-glucosidase 
From 1 mg/ml stock solution different concentrations (5–1000 
μg/ml) of ethyl acetate and n-butanol fractions of B. noctiflora/ 
standard Acarbose in 5 % dimethyl sulfoxide. Five hundred micro 
liters of the test/standard were added to 500 μl of α-glucosidase 
(1U/ml) and was incubated for 5 min at room temperature. Then 
added 500 μl (37 mM) maltose solutions and incubated for 30 min. 
After that 1 ml of the glucose, kit reagent was added to the reaction 
mixture and kept aside for 15 min. 1 ml of Tris buffer was then 
added to the mixture. The absorbance was then measured at 505 nm 
against the reagent blank. The α-glucosidase inhibition was 
expressed as a percentage of inhibition, and the assays were carried 
out in triplicate. The IC50
In vivo antidiabetic studies 
 values were determined by linear 
regression plots with varying concentration of plant fraction against 
percentage inhibition [14]. The percentage inhibition was calculated 
employing the above formula. 
Selection of dose 
LD50 was determined as per OECD guidelines for fixing the dose for 
biological evaluation. The LD50
Animals 
 of the ethyl acetate fractions of B. 
noctiflora (EAFBN) falls under category 4 values with no death and 
no signs of acute toxicity at doses of 2000 mg/kg. The biological 
evaluation of the fraction was carried out at dose levels of 100, 200 
and 400 mg/kg body weight. 
Throughout the experiment, experimental rats were processed in 
accordance with the instruction given by our institutional ethics 
committee for the purpose of control and supervision on 
experiments on animals (CPCSEA) [15]. Healthy Wister rats (150-
200g) were used for the study. Animals were kept in standard 
polypropylene cage and maintained under standard laboratory 
conditions of temperature (24±1°C), 12 h dark like cycles, standard 
diet and water ad libitum. The study protocol was approved by the 
institutional ethical committee (JKKMMRFCP/IAEC/2013/013) and 
all the procedure was performed in accordance with the 
recommendations for the proper care and use of laboratory animals. 
Oral glucose tolerance test (OGTT) 
Rats were divided into five groups of 6 animals each. The 1st group 
received normal saline of 1% of Tween 80, 2nd
Preparation of High-fat diet (HFD) 
 group was 
administered Glibenclamide (10 mg/kg, p. o.) and remaining groups 
received EAFBN at 100 mg/kg, 200 mg/kg and 400 mg/kg, p. o. All 
groups received a glucose solution (2g/kg) 30 min after the 
administration of tests drug. The blood sample was withdrawn from 
tip of tail and blood glucose levels were estimated at 30,60,90 and 
120 min using one touch glucometer (SD check, India). 
High-fat diet (HFD) was prepared as per Gandhi et al. [16] and 
consisted of 73% of a normal diet, 25% of coconut oil and 2% of 
dietary cholesterol, all of the commercial grade. 
Development of HFD and low dose of streptozotocin (STZ) 
treated type 2 diabetic rats  
The animals were fed with high fat diet once a day for two weeks, 
followed by type 2 diabetes mellitus was induced in overnight fasted 
rats administering a single dose of freshly prepared solution of 
Streptozotocin (40 mg/kg. b.w. i. p) in 0.1 Mol/l of cold citrate buffer 
(pH 4.5). The STZ treated animals were allowed to drink 5% glucose 
solution overnight to drug-induced hypoglycemia. After 7 d of 
injection of STZ rats with moderate diabetes, having persistent 
glycosuria and hyperglycemia (blood glucose>250 mg/dl) were used 
for further experimentation [17]. 
Experimental design 
The rats were divided into seven groups of six rats (n=6) each. 
Group 1 and Group 2 served as normal control rats, and Diabetic 
control rats were given 1 ml of 1% Tween 80. Group 3 served as 
High-fat normal control was given 1 ml of 1% Tween 80. Group 4 
served as standard and was treated with 1% Tween 80 containing 
Glibenclamide (10 mg/kg). Group 5, Group 6 and Group 7 were treated 
with doses of (100 mg/kg, 200 mg/kg 
Blood samples were collected from the tip of rat tail and blood 
glucose levels were estimated on 0
and 400 mg/kg) EAFBN in 1% 
of Tween 80. The treatments were continued daily for 28 d. 
th, 7th, 14th,21st and 28th days of 
treatment using One touch glucometer (SD check, India). Body 
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weight was measured initially and during the treatment period. On 
the 29th day blood was collected by a retro-orbital puncture from the 
inner canthus of the eye under mild ether anesthesia using capillary 
tubes in fresh vials and the serum separated. Serum parameters like 
triglycerides, total cholesterol, urea, creatinine, insulin, low-density 
lipoproteins (LDL), high-density lipoproteins (HDL), alkaline 
phosphatase (ALP), aspartate transaminase (AST) and alanine 
transaminase (ALT) were determined using standard kits obtained 
from Agappe Diagnostics, Cochin, India using a semi auto analyser 
(Maxlyzer ultra). Immediately after the blood collection, the animals 
were sacrificed under mild ether anesthesia; Hemidiaphragm; 
pancreas and liver tissues were dissected out for further studies.  
Estimation of glycogen and glucose uptake by hemidiaphragm 
and liver glycogenolysis 
The liver tissue was separated into two portions, one for the 
glycogen estimation and another for liver glycogenolysis. The liver 
tissue was homogenized in 5 % w/v trichloroacetic acid and its 
glycogen content was determined by the method [18]. The 
hemidiaphragm and liver tissues were carefully excised and placed 
immediately in ice cooled perfusion solution with the following 
composition: NaCl (0.687%), KCl (0.04%), MgSO4 (0.014%), CaCl2 
(0.028%), NaHPO4 (0.014%) and NaHCO3 (0.21%). Glucose was 
added to another batch of the perfusate at a concentration of 400 
mg%. This perfusate was used to study the glucose uptake/transfer 
processes. The hemidiaphragm were incubated at 37 °C for 1.5 h 
with appropriate aeration to enable stirring and also to provide 
oxygen to the tissue. At the end of the incubation period, glucose 
concentration in the perfusate was assayed. The hemidiaphragm 
were removed, rinsed in water and dried in an oven at 55–60 °C for 
4–5 h or till a constant weight was obtained. The glucose uptake 
during the incubation period was calculated in terms of mg per100 
mg dry weight of the hemidiaphragm. Similarly, liver slices were 
incubated in the enriched glucose perfusate. The glucose 
concentration in the perfusate over the incubation period was 
determined in terms of mg per g of dry weight of liver [19]. 
Histopathological studies of pancreatic tissues  
Pancreatic tissues isolated from rats were used for histopathological 
studies. The tissue in each group was cut into small portions 
measuring 1 cm, fixed with 10 % formaldehyde solution, dehydrated 
in gradually increasing concentrations of ethanol (50–100 %), 
cleared in xylene and embedded in paraffin. Sections of 5 μm 
thickness were prepared. Haematoxylin and eosin were used for 
staining and later the microscopic slides of pancreatic tissue were 
photographed under 100x magnifications. 
Statistical analysis 
All determinations for in vitro study were carried out in triplicate 
and the values are expressed as mean±SEM and inhibitory 
concentration (IC50) was carried out with GraphPad Prism. In vivo 
study, the results were expressed as mean±SEM for 6 rats in each 
group. Statistical analysis of the results was carried out using 
GraphPad In Stat software by one-way analysis of variance (ANOVA) 
followed by Dunnett’s test. The level of significance was set at P<0.05. 
RESULTS 
In vitro inhibition of α-amylase 
The fractions of EAFBN and NBFBN, elicited a dose-dependent 
inhibition of α-amylase enzyme activity. The α-amylase inhibitory 
effect of the EAFBN was found to be ranging from 14.62 % to 
84.63% when studied at concentrations 5–1000 μg/ml. At the same 
concentration range, the inhibitory effect of NBFBN was found to be 
ranging from 12.58% to 82.25%, whereas the effect of standard drug 
Acarbose ranged from 19.60% to 88.89%. The IC50 of EAFBN was 
found to be 114.7±0.15 μg/ml, whereas NBFBN showed at 147.8±0.40 
μg/ml. The IC50
The fractions of EAFBN and NBFBN, elicited a dose-dependent 
inhibition of α-glycosidase enzyme activity. The α-glycosidase 
inhibitory effect of the EAFBN was found to be ranging from 12.47 % 
to 83.83% when studied at concentrations 5–1000 μg/ml. At the 
same concentration range, the inhibitory effect of NBFBN was found 
to be ranging from 11.55% to 81.41%, whereas the effect of 
standard drug Acarbose ranged from 18.44% to 88.20%. The IC
 of Acarbose was found to be 88.92±0.25 μg/ml (fig. 1). 
In vitro inhibition of α-glycosidase 
50 of 
EAFBN was found to be 104.93±0.28 μg/ml, whereas NBFBN 
showed at 138.96±0.17 μg/ml. The IC50 of Acarbose was found to be 
97.96±0.51μg/ml (fig. 2). 
 
 
Fig. 1: In vitro α-amylase inhibitory activity of Barleria 
noctiflora fraction. Values are expressed as the mean of 
triplicate measurement. EABN–Ethyl acetate fraction of Barleria 
noctiflora; NBBN–N-butanol fraction of Barleria noctiflora 
 
 
Fig. 2: In vitro α-glycosidase inhibitory activity of Barleria 
noctiflora fraction. Values are expressed as the mean of 
triplicate measurement. EABN–Ethyl acetate fraction of Barleria 
noctiflora; NBBN–N-butanol fraction of Barleria noctiflora 
 
Selection of an active fraction used in vivo antidiabetic studies 
The fractions of EAFBN and NBFBN showed the dose-dependent 
inhibition in the α-glycosidase and α-amylase enzyme. These 
fractions were comparatively EAFBN fraction shows less IC50
The body weight was slightly increased in the normal control and 
High-fat diet control significantly increased compared to initial body 
weight, whereas in the diabetic control rats there was a significant 
decrease in the body weight. Standard as well as the EAFBN 
treatment significantly (P<0.01) prevented this reduction in body 
weight. Although there is a marginal reduction in the weight of 
animals in these groups, compared to initial body weights (table 2). 
 value 
and preferable effect than NBFBN, so EAFBN was selected in vivo 
antidiabetic studies. 
In vivo antidiabetic studies 
Oral glucose tolerance test (OGTT) 
The EAFBN doses of 100, 200 & 400 mg/kg have shown increase the 
tolerance for glucose and blood glucose levels were significantly 
reduced in the dose dependent after oral administration (2g/kg). 
The tested drug of EAFBN 400 mg/kg and standard drug showed 
significantly (p<0.01) activity at 30 min onwards and at the time of 
120 min all the dose of the drug shows significant (p<0.01) activity 
(table 1). 
Effect of ethyl acetate fraction on STZ induced diabetic rats 
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Table 1: The effects of EAFBN on oral glucose tolerance test (OGTT) in rats 
Groups Fasting blood glucose (mg/dl) at different time (min) after the treatment 
0 30 60 90 120 
Normal control 85±1.71 141.16±1.24 134.33±2.02 127.66±1.43 121.16±2.01 
Glibenclamide (10 mg/kg) 83.83±1.66 115.66±1.45** 105.16±0.90** 94.33±1.20** 85.16±0.79** 
EAFBN (100 mg/kg) 84.66±1.83 141.33±1.68 133.33±1.68 124.5±1.33 112.33±2.02** 
EAFBN (200 mg/kg) 87.16±0.94 134.5±0.76* 127.66±0.84* 119.5±0.95** 107.5±1.52** 
EAFBN (400 mg/kg) 82.16±1.35 127.16±1.86** 117.33±2.10** 108.33±1.85** 94.34±1.28** 
Values are given in mean±SEM for groups of six animals each. **p<0.01, * p<0.05 denotes when compared to control (One-way ANOVA followed by 
Dunnett test). EAFBN–Ethyl acetate fraction of Barleria noctiflora. 
 
Table 2: The effects of EAFBN on body weight in HFD/STZ–induced diabetic rats 
Groups Body weight (g) 
Initial Final (% Change) 
Normal control 165.5±3.53 180.66±3.80 (+15.16) 
Diabetic control 191.66±1.20 141.16±1.85 (-50.50)** 
HFD control 184.16±2.98 204±2.93 (+19.84)** 
Diabetic+Glibenclamide (10 mg/kg) 190±2.22 177.5±2.23 (-12.5)** 
Diabetic+EAFBN (100 mg/kg) 192.33±1.97 157±1.63 (-35.33)** 
Diabetic+EAFBN (200 mg/kg) 193±1.69 165.83±0.90 (-27.17)** 
Diabetic+EAFBN (400 mg/kg) 192.33±2.09 172.5±1.64 (-19.83)** 
Values are given in mean±SEM for groups of six animals each. **p<0.01 denotes when all the group was compared with Normal control (One-way 
ANOVA followed by Dunnett test). EAFBN–Ethyl acetate fraction of Barleria noctiflora. 
 
The diabetic rats showed a significant increase in the fasting blood 
glucose levels and the HFD control rats showed a slightly significant 
increase when compared to normal control. The treatment of 
diabetic rats with the standard and EAFBN resulted significant 
(P<0.01) decrease in the fasting blood glucose levels from the 7th
 
 day 
onwards and the values were compared to diabetic control (table 3). 
Table 3: The effects of EAFBN on fasting blood glucose levels in HFD/STZ–induced diabetic rats 
Groups Fasting blood glucose (mg/dl) 
0 d 7 d 14 d 21 d 28 d 
Normal control 87.83±1.07 89±1.36 88±0.94 86.16±0.94 88.17±0.70 
Diabetic control 285.16±3.32** 292.16±3.38** 300.83±4.67** 303.33±4.67** 310.33±2.57** 
HFD control 107.83±2.76** 101.67±1.96 102.5±1.66* 102.83±1.10* 105.67±1.20** 
Diabetic+Glibenclamide (10 mg/kg) 282.67±3.95 207.66±6.52** 181.33±4.54** 150.5±4.00** 125.83±2.04** 
Diabetic+EAFBN (100 mg/kg) 282.5±4.61 246.67±3.62** 226.33±4.19** 195.5±3.95** 179.17±3.53** 
Diabetic+EAFBN (200 mg/kg) 275.5±4.75 240.83±2.49** 203.5±3.95** 172.16±3.51** 142±3.76** 
Diabetic+EAFBN (400 mg/kg) 278.33±6.50 216.66±4.29** 192.33±4.52** 157.5±5.16** 131±3.58** 
Values are given in mean±SEM for groups of six animals each. **p<0.01, * p<0.05 denotes when diabetic control and HFD control was compared 
with the Normal control and treated groups were compared with the diabetic control on a corresponding day (One-way ANOVA followed by 
Dunnett test). EAFBN–Ethyl acetate fraction of Barleria noctiflora. 
 
The untreated diabetic rats and HFD rats showed a significant 
(P<0.01) elevated in the levels of cholesterol, triglycerides and LDL 
but decrease in HDL when compared to the normal control of rats, 
but HFD rats were a slightly same effect, decreased than diabetic 
control rats. Treatment of Glibenclamide and EAFBN showed a 
marked reversal of changes in the serum lipid parameters as 
compared to diabetic rats (table 4). The activities of serum 
enzymes like ALP, AST and ALT were significantly (P<0.01) 
increased in diabetic control when compared to normal control 
rats. The Glibenclamide and EAFBN treated rats showed a 
significant (P<0.01) reduction in the serum enzymes when 
compared to diabetic control rats (table 5). 
 
Table 4: The effects of EAFBN on serum lipid profile in HFD/STZ–induced diabetic rats 
Groups Cholesterol (mg/dl) Triglycerides (mg/dl) LDL (mg/dl) HDL (mg/dl) 
Normal control 110.67±1.45 86.66±2.20 89.66±1.60 37.33±1.02 
Diabetic control 291.66±3.72** 244.33±4.02** 195.5±3.29** 24.33±1.25** 
HFD control 149.5±6.00** 146.5±2.40** 99±1.41* 34.66±1.02 
Diabetic+Glibenclamide (10 mg/kg) 154.33±1.83** 109.33±2.14** 79.83±1.35** 46.16±1.47** 
Diabetic+EAFBN (100 mg/kg) 188.66±2.78** 189.16±2.04** 140.83±1.81** 33.16±1.42* 
Diabetic+EAFBN (200 mg/kg) 174.5±2.07** 156.16±2.38** 104.66±1.76** 40.33±1.22** 
Diabetic+EAFBN (400 mg/kg) 159.83±2.19** 130±2.65** 91.5±2.54** 45±1.73** 
Values are given in mean±SEM for groups of six animals each. **p<0.01, * p<0.05 denotes when diabetic control and HFD control was compared 
with the Normal control and treated groups were compared with the diabetic control on a corresponding day (One-way ANOVA followed by 
Dunnett test). EAFBN–Ethyl acetate fraction of Barleria noctiflora. 
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Table 5: The effects of EAFBN of serum marker enzymes in HFD/STZ–induced diabetic rats 
Groups ALP (IU/l) AST (IU/l) ALT (IU/l) 
Normal control 62±1.80 77.5±1.76 40±2.08 
Diabetic control 156±3.89** 183.5±3.00** 126.5±1.56** 
HFD control 68.33±1.60 79.16±1.30 42.33±1.66 
Diabetic+Glibenclamide (10 mg/kg) 66.66±1.28** 79.66±1.58** 44.5±1.38** 
Diabetic+EAFBN (100 mg/kg) 117.16±2.30** 150±3.16** 92.5±1.54** 
Diabetic+EAFBN (200 mg/kg) 90±2.06** 101.66±2.20** 68.66±1.52** 
Diabetic+EAFBN (400 mg/kg) 68.66±2.71** 82.16±1.81** 52.5±1.66** 
Values are given in mean±SEM for groups of six animals each. **p<0.01 denotes when diabetic control and HFD control was compared with the 
Normal control and treated groups were compared with the diabetic control on a corresponding day (One-way ANOVA followed by Dunnett test). 
EAFBN–Ethyl acetate fraction of Barleria noctiflora. 
 
Serum urea, serum creatinine and HbA1c levels were significantly 
(P<0.01) decreased and serum insulin levels were significantly 
(P<0.01) increased by Glibenclamide and EAFBN treated rats when 
compared to diabetic rats. Diabetic control rats were reversal 
changes when compared to normal control (table 6). 
There was a significant marked reduction in the liver glycogen levels 
of diabetic rats from 4.02 g/100 g tissue (in normal control rats) to 
2.27g/100g tissue. Glibenclamide treatment elicited 3.77g/100g 
increase in liver glycogen levels; EAFBN (100 mg/kg) treatment 
showed 2.83g/100g increase while at 200 mg/kg and 400 mg/kg 
there was 3.17g/100g and 3.72g/100g increase in liver glycogen 
levels when compared with the untreated diabetic rats. 
Hemidiaphragm taken from rats treated with EAFBN and 
Glibenclamide showed a significant (P<0.01 enhancement of the 
glucose uptake process as compared to untreated diabetic rats. Also, 
both EAFBN and Glibenclamide treated rats showed a significant 
(P<0.01) inhibitory effect on glycogenolysis in liver tissue (table 7). 
 
Table 6: The effects of EAFBN on serum profile in HFD/STZ–induced diabetic rats 








Normal control 26.83±1.22 0.51±0.01 3.55±0.16 6.07±0.07 
Diabetic control 63.66±1.62** 1.41±0.02** 1.53±0.15** 11.97±0.03** 
HFD control 30.83±0.87 0.61±0.02** 3.21±0.10 6.85±0.04** 
Diabetic+Glibenclamide (10 mg/kg) 35.67±1.33** 0.58±0.01** 2.83±0.13** 6.97±0.03** 
Diabetic+EAFBN (100 mg/kg) 39.50±1.11** 1.05±0.01** 2.15±0.11** 8.64±0.03** 
Diabetic+EAFBN (200 mg/kg) 37±1.36** 0.77±0.01** 2.36±0.07** 7.91±0.03** 
Diabetic+EAFBN (400 mg/kg) 34.50±1.31** 0.67±0.01** 2.75±0.14** 7±0.06** 
Values are given in mean±SEM for groups of six animals each. **p<0.01 denotes when diabetic control and HFD control was compared with the 
Normal control and treated groups were compared with the diabetic control on a corresponding day (One-way ANOVA followed by Dunnett test). 
EAFBN–Ethyl acetate fraction of Barleria noctiflora. 
 
Table 7: The effects of EAFBN on Liver glycogen, Glucose uptake by hemidiaphragm and Glucose transport by liver in HFD/STZ–induced 
diabetic rats 
Groups Liver glycogen  
(g/100g of wet tissue) 
Glucose uptake by hemidiaphragm 
(mg/100 mg) 
Glucose transport by liver 
(mg/g) 
Normal control 4.02±0.10 16.78±0.30 27.05±0.22 
Diabetic control 2.27±0.15** 4.76±0.20** 42.03±0.85** 
HFD control 3.98±0.06 15.51±0.40* 28.83±0.35 
Diabetic+Glibenclamide  
(10 mg/kg) 
3.77±.073** 16.31±0.24** 19.13±0.30** 
Diabetic+EAFBN (100 mg/kg) 2.83±0.05** 9.46±0.27** 26.36±0.51** 
Diabetic+EAFBN (200 mg/kg) 3.17±0.11** 12.61±0.22** 23.53±0.50** 
Diabetic+EAFBN (400 mg/kg) 3.72±0.09** 15.83±0.44** 19.36±0.28** 
Values are given in mean±SEM for groups of six animals each. **p<0.01, * p<0.05 denotes when diabetic control and HFD control was compared 
with the Normal control and treated groups were compared with the diabetic control on a corresponding day (One way ANOVA followed by Dunnett 
test). EAFBN–Ethyl acetate fraction of Barleria noctiflora. 
 
Histopathological study 
The histopathological studies of the pancreatic tissues are shown in 
(fig. 3). Normal rats showed the normal architecture of the pancreas 
with the preserved islet of Langerhans cells (fig. 3A). Induction of 
diabetes using Streptozotocin resulted in hyalinization of islets of 
Langerhans cells with focal mild degenerative changes, mild fibrosis, 
dilated and congested vessels along with focal chronic inflammatory 
cell infiltrate in diabetic rats (fig. 3B). HFT control rats showed mild 
edema of islets of Langerhans cells, thick-walled and congested 
vessels, focal lymphocytic infiltrate exhibiting focal edematous 
changes (fig. 3C). The abnormal histopathology of the pancreas due 
to Streptozotocin-induced diabetes was reversed in the 
Glibenclamide, and EAFBN treated diabetic animals.  
The recovery of standard Glibenclamide treated group was evident 
as near normal architecture with preserved islet cells and mild 
edema (fig. 3D). The resulted in EAFBN (100 mg/kg, 200 mg/kg & 
400 mg/kg) treated groups mild hyalinization islets of langerhans 
cells with focal mild degenerative changes when compared to 
untreated diabetic rats. It can be noted that the islets of langerhans 
cells regenerated in the treatment groups (fig. 3E,3F& 3G). 
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Fig. 3: Histology of control and treated rat pancreas of antidiabetic studies. A) Control rat, B) Diabetic control, C) HFT control, D) 
Standard, E) EAFBN (100 mg/kg), F) EAFBN (200 mg/kg) and G) EAFBN (400 mg/kg) 
 
DISCUSSION 
The in vitro α-amylase and α-glucosidase inhibitory studies 
demonstrated EAFBN had an inhibitory activity of the intestinal 
digestive enzyme. The percentage inhibition showed a dependant 
concentration reduction. These enzymes are responsible in 
hydrolyzing dietary starch into maltose which then breaks down to 
glucose prior to absorption. Since α-amylases play an important role 
in the starch breakdown in human beings and animals, the presence 
of such inhibitors in foodstuffs may be responsible for impaired 
starch digestion. The α-amylase inhibitor may be of value as novel 
therapeutic dietetic agents [20]. Acarbose-like drugs that inhibit α-
glucosidase present in the epithelium of small intestine have been 
demonstrated to decrease postprandial hyperglycemia and improve 
impaired glucose metabolism without promoting insulin secretion in 
type 2 diabetic patients. These medications are most useful for 
people who have just been diagnosed with type-II diabetes and who 
have blood glucose levels slightly above the level considered serious 
for diabetes [21]. They are also useful for people taking sulfonylurea 
medication, who need additional medication to keep their blood 
glucose level within a safe range. Therefore, the retardation and 
delay of carbohydrate absorption with a plant-based α-glucosidase 
inhibitor offers a prospective therapeutic approach for the 
management of type-II diabetes mellitus. 
The metabolic syndrome is characterized pathological changes 
including obesity, hypertriglyceridemia, impaired glucose tolerance 
and insulin resistance. A modified high-fat diet was adopted to 
induce insulin resistance because the role of HFT in the 
development of diabetic complications and injection of a single dose 
of STZ induced a type 2 diabetic state similar to prediabetic, insulin 
resistant state in humans.  
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In the in vivo study the reduction in the body weight in 
Streptozotocin-induced diabetic rats can be attributed to muscle 
wasting, dehydration, reduced body fat, reduction in adipose tissue 
and excessive breakdown of proteins [22]. There was a reversal of 
this loss in body weight in the diabetic animals treated with the 
EAFBN and Glibenclamide.  
The mechanism in diabetes involved the overproduction (excessive 
hepatic glycogenolysis and gluconeogenesis) and decreased 
utilization of glucose by tissue. STZ is a slightly cytotoxic agent of 
pancreatic β cells and selectively destroys the pancreatic insulin 
secreting β cells, leaving less active cells and resulting in a diabetic 
state. Hence, in this study, observed an increasing level of blood 
glucose in STZ induced rats. The hyperglycemic activity of EAFBN 
has shown significant (p<0.01) fall in blood glucose level for 7th
Hyperglycemia is accompanied with dyslipidemia and represents a 
risk factor for coronary heart diseases. The abnormality high level of 
serum lipids is mainly due to the uninhibited action of lipolytic 
hormones on the fat depots, mainly due to the action of insulin. 
Under normal condition, insulin activates the enzyme lipoprotein 
lipase, which hydrolysis triglycerides. However, in diabetic state 
lipoprotein lipase is not activated due to insulin deficiency resulting 
in hypertriglyceridemia and insulin deficiency is also associated 
with hypercholesterolemia due to metabolic abnormalities [24]. The 
dyslipidemia is characterized by an increase in TC, TG, LDL and fall 
in HDL. This altered serum lipid profile was reversed towards 
normal after treatment with EAFBN.  
 day 
onwards at all the doses of 100 mg/kg, 200 mg/kg and 400 mg/kg 
per oral [23]. 
The excess of free fatty acids during diabetes is found to be directly 
toxic to hepatocytes [25]. As a result the enzyme like the ALP, AST 
and ALT may leak from the hepatocytes into the circulation where 
their levels become elevated [26]. The elevation of ALT is attributed 
to impairment in insulin signaling rather than hepatocytes injury. In 
the present study increase, the levels of these enzymes in diabetic 
control rats were decreased when treated with the EAFBN similar to 
Glibenclamide. EAFBN may bring about the hypoglycemic effects 
through insulin secretion from the remnant β cells and regenerate β 
cells due to increased peripheral glucose utilization and insulin 
stimulatory effects [27, 28]. Increase the glycogen in the liver can be 
brought about by an increase in glycogenesis and decrease in 
glycogenolysis. Hemidiaphragm taken from rats treated with EAFBN 
and Glibenclamide showed a significant enhancement of the glucose 
uptake and significant inhibitory effect on glucose transport 
(glycogenolysis) in liver compared to diabetic control. 
STZ administration results in DNA damage in β-cells of pancreatic 
islets due to its potent alkylating properties [29]. Histopathologically 
the damage was seen in untreated diabetic rats. There was the 
regeneration of β-cells in EAFBN and Glibenclamide treatment 
groups since the cells recovered from the initial injury. The 
regeneration of the β-cells destructed by STZ are probably due to the 
fact that pancreas contains stable cells which have the capacity to 
regenerate. Therefore, the surviving cells can proliferate to replace 
the lost cells [30]. 
CONCLUSION 
In conclusion, the diabetes mellitus is the major metabolic disorder 
in all over the world. Hence, the result of this present study suggests 
that High-fat diet was one of the complicating induced type 2 
diabetes. Barleria noctiflora was a potent hypoglycemic agent and 
beneficial in the control of diabetes-related abnormalities such as 
hyperglycemia, lipid abnormalities, hepatic changes and 
histopathological changes in the pancreas of HFD/STZ-induced 
non-genetic rat model of type 2 diabetes mellitus. However, these 
findings make the Barleria noctiflora was safe for oral consumption 
and elicit hypoglycemic activity, further research and would result in 
the discovery of lead compounds useful in treating diabetes mellitus. 
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